Marker Therapeutics Inc (MRKR)

[Sugarshaker]

This article was from 1st. qtr. 2017,
This is the first study to evaluate the combination of a cancer vaccine with a checkpoint inhibitor. The single-arm study has enrolled 27 out of the planned 40 women whose cancer progressed after receiving platinum-based therapy. If successful in this extremely difficult-to-treat patient population, there is potential for this novel combination regimen to be a breakthrough for these patients, who have very poor survival prognosis and no available treatment options. Results from the planned interim analysis are expected to be available in the third quarter 2017. If the safety profile remains favorable and there are sufficient signs of tumor response, patient enrollment will resume and TapImmune expects the study to be completed as planned in 2018.